Caplin Point Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Smallcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
At its May 15, 2025 board meeting, Caplin Point Laboratories announced strong FY25 results. Consolidated total revenue rose 15.5% year-on-year to ₹2,033.9 Cr, while consolidated profit after tax grew 17.3% to ₹541.1 Cr. EBITDA margin expanded to 36.5% (from 35.1% in FY24), and basic EPS jumped 17.2% to ₹70.57. On a standalone basis, revenue from operations grew over 20% to ₹752.4 Cr. Operating cash flow stood at ₹432.4 Cr, with free cash reserves of ₹1,180 Cr. The board declared an interim dividend of ₹3 per share (150% on a ₹2 face value), with May 30, 2025 set as the record date. Statutory auditors Brahmayya & Co issued an unmodified (clean) audit opinion on both standalone and consolidated results. The company also appointed M/s. M Alagar & Associates as secretarial auditors for a 5-year term starting FY26, subject to shareholder approval.
Strong double-digit growth in revenue, profits and margins, paired with a generous 150% interim dividend and a clean audit opinion, are positive signals for shareholders. Healthy free cash reserves of ₹1,180 Cr and zero significant debt underscore the company's financial strength and likely support steady investor sentiment.